bpc-157 heart therapy in the cardiovascular system. The heart-protecting eff – Synthagen PL An FDA Committee Just Voted

BPC-157 does not have approval for any medical use in the United States, which means it has not met FDA standards for safety, effectiveness, and quality

The main ongoing studies: REDEFINE 1 , Phase 3 obesity without T2D (results 20242025, preliminarily 25.3 %) REDEFINE 2 , Phase 3 obesity + T2D REDEFINE 3 , Phase 3 cardiovascular outcome trial (n~7000) Stand-alone clinical development of Cagrilintide is limited , Novo Nordisk is primarily investing in the CagriSema combination

In theory, yes, as they operate through completely different mechanisms

However, even if you eat enough to get the recommended dose (2.4 micrograms in people 14 and older), older adults and people with gastrointestinal issues may have problems absorbing it properly